Diversified health care player Baxter (NYSE: BAX )
has done alright so far this year, up almost 10% and ahead of the
S&P 500, but there is still a fair bit of skepticism on the name.
Analysts continue to fret that Biogen Idec (NASDAQ: BIIB )
will grab considerable market share in hemophilia and that generic
competition for other products will add to the revenue erosion. Although
this is a challenging period for the company ahead of data on is own
long-acting hemophilia product, approval of HyQ, and real leverage in
the renal business, Baxter shares continue to look a little undervalued
for patient long-term investors.
Read more here:
Why the Market is Wrong About Baxter Stock
No comments:
Post a Comment